Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes

NCT07017933 · tracked via the Priya Life Science USA tracker

Sponsor

3ive Labs

Phase

Not applicable

Started

2025-07-16

Last updated

2026-03-19

Condition(s) studied

Renal Impairment After Cardiac SurgeryRenal ImpairmentAcute Kidney Injury

Investigational drug(s) / intervention(s)

Renal assist device

Renal assist device: The JuxtaFlow RAD includes two endoscopically placed ureteral catheters connected to a bedside pump system. The catheters are designed to deliver a mild, controlled negative pressure (-15 mmHg ± 2mmHg) into the renal pelvis of each kidney for up to 72 hours. This pressure is designed to diffuse through each of the million nephrons lowering intratubular pressure thereby improving the filtration gradient at the glomerulus while supporting overall kidney function.

Study summary

Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively. This in turn is associated with an increased risk of prolonged intensive care unit (ICU) length of stay, other comorbidities including surgical complications and 30-day mortality. Renal impairment is generally identified based on an increase in serum creatinine concentration and/or a certain magnitude decrease in estimated glomerular filtration rate (eGFR).

The JuxtaFlow® Renal Assist Device (RAD) is designed to sustain or enhance glomerular filtration perioperatively for patients with renal insufficiency by applying a mild controlled negative pressure to the collecting system via the renal pelvis, thereby increasing effective filtration pressure and reducing tubular pressure. This mechanism is designed to support the kidneys' functions during times of renal stress that would be associated with intrarenal edema, volume overload, increased venous pressure, and inflammatory response. By supporting renal function, specifically during the acute stress of CPB, JuxtaFlow holds promise to protect nephron function, decrease renal hypoxia, and provide multifactorial kidney function support to maintain their ability to manage future stress.

Eligibility

Sex

ALL

Min age

22 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: To be eligible for participation in this study, an individual must meet all the following criteria: 1. A candidate for elective or urgent on-pump coronary artery bypass grafting (CABG) and/or valvular surgery 2. Male or Female age 22 to 85 years 3. Estimated glomerular filtration rate (eGFR) 15 - 60 mL/min/1.73m2 4. Signed and dated informed consent 5. Female patients of childbearing potential must: 1. have negative pregnancy test at the informed consent visit, 2. be using previously initiated approved and effective contraception from the informed consent visit through completion of the study \*The only recommended contraception is condoms. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Any individual, or their legally authorized representative (LAR), who does not understand the requests and risks of participating in the clinical trial or is unable to give informed consent 2. Pregnancy or lactation 3. Prior cardiac surgery within the last 6 months 4. Hemodynamic instability as determined by the Principal Investigator 5. Immunosuppression 6. Active infections (e.g. HIV, Tbc, and all types of Hepatitis) 7. History of polycystic kidney disease 8. Patients with only one active kidney or one poorly functioning kidney 9. Evidence of current kidney obstruction (e.g., Kidney stones) 10. Evidence of current hydronephrosis 11. Active upper and/or lower urinary tract infections 12. Malignancy; oncological Surgery within 5 years or ongoing antitumoral treatment 13. Ongoing sepsis or endocarditis 14. Patients who have an expected 30-day postoperative mortality greater than 10% as determined by the Principal Investigator 15. Any secondary condition as determined by the investigator that would place the subject at an increased risk or preclude the subject's full compliance with the study procedures, including injuries to the urinary organs and/or external genitals; or severe BPH 16. Unexplained/unexpected gross hematuria as determined by the Investigator 17. Current or planned treatment with an investigational drug (IND), device (IDE), or other investigational intervention within 3 months prior to or during participation in this clinical trial 18. Patients who have a current unrepaired ureteral avulsion as determined by the investigator 19. Patients otherwise contraindicated for urological interventions, including ureter guidewire placement via bladder cystoscopy and ureteral catheterization, or otherwise contraindicated for any of the other study procedures

Primary outcome measure(s)

Mean Peak Percent Change in Serum Creatinine — 96 hours peri-operative
The mean peak percent change in serum creatinine from baseline values (prior to treatment) within the first 96 hours post-surgery for JuxtaFlow treated subjects as compared to controls.
Incidence of Treatment-Emergent Adverse Events — From enrollment to post-operative day 30
The characterization and comparison of all types, frequency, and severity of adverse events (AEs) associated with JuxtaFlow treatment and controls.

Trial sites (7)

Facility	City	Region	Status
Cleveland Clinic Florida	Weston	Florida	Recruiting
University of Michigan	Ann Arbor	Michigan	Recruiting
University of North Carolina	Chapel Hill	North Carolina	Recruiting
University of Cincinnati	Cincinnati	Ohio	Recruiting
American Heart of Poland	Bielsko-Biala	Poland	Recruiting
Poznan University of Medical Sciences	Poznan	Poland	Active Not Recruiting
Medicover Hospital	Warsaw	Poland	Recruiting

Other trials for the same condition

Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid Starting soon

ProNephro NGAL Test for Early Detection of Acute Kidney Injury in Adult ICU Patients (ALPACA) Enrolling by invitation

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function Recruiting

A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions Recruiting

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07017933 on ClinicalTrials.gov ↗ ← All trials in the USA